Amlodipine Bristol Lab Tablets (Amlodipine Besilate)

First of a kind Amlodipine 2.5mg tablets expands your dosing options for your patients

Prescribing Information can be found here

About amlodipine

Amlodpine (active ingredient, amlodipine besilate) is indicated for adults with hypertension, chronic stable angina pectoris and vasospastic (Prinzmetal’s) angina. Indicated in paediatric patients* with hypertension from 6 – 17 years of age.

*see special populations

Amlodipine recommended dosage and administration

Amlodipine is available in tablet form in a 2.5mg dose for oral administration.

Adults

For both hypertension and angina the usual initial dose for adults is 5mg once daily which may be increased to a maximum dose of 10mg once daily depending on the individual patient’s response.

Check 2.5 mg
Check Indication: Hypertension, chronic stable angina pectoris and vasospastic (Prinzmetal’s) angina
Check Suitable for Vegetarians
Check Suitable for Vegans
Check Gluten Free
Check Regulatory Status POM

Special populations

Paediatric patients


The recommended antihypertensive oral dose in paediatric patients ages 6-17 years is 2.5mg once daily as a starting dose, up-titrated to 5mg once daily if the blood pressure goal is not achieved after 4 weeks. Doses in excess of 5mg daily have not been studied in paediatric patients. No data available in children under 6 years of age.

Hepatically impaired patients


Dosage recommendations have not been established in mild to moderate hepatic impairment; dose selection should be cautious and should start at the lower end of the dosing range. Amlodipine should be initiated at the lowest dose and titrated slowly in severe hepatic impairment.

Renally impaired patients


Normal dosage is recommended.

Elderly patients


Normal dosage regimens are recommended in the elderly, but increase of the dosage should take place with care.

.

Contraindications

Hypersensitivity to dihydropyridines derivatives, amlodipine or any of the excipients, severe hypotension, shock (including cardiogenic shock), obstruction of the outflow tract of the left ventricle, (e.g. high grade aortic stenosis), haemodynamically unstable heart failure after acute myocardial infarction.

Please refer to the Summary of Product Characteristics for a list of adverse events, special warnings and precautions for use.

 

How to report adverse events

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk.

Adverse events should also be reported to Bristol Laboratories on Tel: 0044 (0) 1442 200 922 or Email: info@bristol-labs.co.uk